Перспективы использования мезенхимальных стволовых клеток в терапии воспалительных заболеваний кишечника

Я.И. Исайкина, И.И. Саванович, А.В. Сикорский ГУ «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии», УО «Белорусский государственный медицинский университет»

2020 №3 | Лекции

Аннотация

Список литературы

Скачать полнотекстовую статью

В обзоре рассмотрены перспективы использования мезенхимальных стволовых клеток в лечении воспалительных заболеваний кишечника у детей. Проанализированы иммуномодулирующие свойства данных клеток и возможное их влияние на течение воспаления при болезни Крона и язвенном колите, а также результаты применения клеточной терапии для лечения воспалительных заболеваний кишечника в проведенных и проводимых на сегодняшний день доклинических и клинических испытаниях. Положительные результаты применения мезенхимальных стволовых клеток позволяют рассматривать данный вид терапии как перспективный в комплексном лечении воспалительных заболеваний кишечника.

Ключевые слова:

воспалительные заболевания кишечника, болезнь Крона, язвенный колит, мезенхимальные стволовые клетки

Prospects of using mesenchymal stem cells therapy for the treatment of inflammatory bowel diseases in children

The review considered the possible prospects of using mesenchymal stem cells therapy for the treatment of inflammatory bowel diseases in children. Immunomodulatory properties of this type of stem cells and their possible influence on the course of inflammation in case of Crohn's disease and ulcerative colitis, as well as the results of the application of cellular therapy for the treatment of inflammatory bowel diseases in the continuing and in the conducted preclinical and clinical trials were analyzed. The positive results of using the mesenchymal stem cells allow to consider this approach as one of the most promising methods of complex treatment of inflammatory bowel diseases.

Keywords

inflammatory bowel diseases, Crohn's disease, ulcerative colitis, mesenchymal stem cells

1. Mamula, P. Pediatric Inflammatory Bowel Disease / P. Mamula, A. B. Grossman, R. N. Baldassano [et al.] – Third Edition: Springer, 2017. – P. 754.
2. Ruemmele, F. M. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease / F. M. Ruemmele, G. Veres, K. L. Kolho [et al.] // J. Crohns Colitis. – 2014. – Vol. 8, № 10. – P. 1179–1207.
3. Turner, D. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care–An Evidence-based Guideline From European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition / D. Turner, F. M. Ruemmele, E.Orlanski-Meyer [et al.] // J. Pediatr. Gastroenterol. Nutr. – 2018. – Vol. 67. – P. 257–291.
4. Turner, D., Ruemmele F. M., Orlanski-Meyer E. et al. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis–An Evidence-based Consensus Guideline From the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition / D. Turner, F. M. Ruemmele, E. Orlanski-Meyer [et al.] // J. Pediatr. Gastroenterol. Nutr. – 2018. – Vol. 67. – P. 292–310.
5. Benchimol, E. I. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends / E. I. Benchimol, K. J. Fortinsky, P. Gozdyra [et al.] // Inflamm Bowel Dis. – 2011. – Vol. 17. – P. 423–439.
6. Buderus, S. Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry / S. Buderus, D. Scholz, R. Behrens [et al.] // Dtsch Arztebl Int. – 2015 Feb 20.;112(8). – P. 121–7.
7. Ng, S. C. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:a systematic review of population-based studies /S. C. Ng, H. Y. Shi, N. Hamidi [et al.] // Lancet. – 2018. – Dec 23;390(10114). – P. 2769–2778.
8. Michael, J. Rosen. Inflammatory Bowel Disease in Children and Adolescents / Michael J. Rosen, Ashish Dhawan, Shehzad A. Saeed // JAMA Pediatr. – 2015. – Nov; 169(11). – P. 1053–1060.
9. Levine A. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases /A. Levine, R. Sigall Boneh, E. Wine // Gut. – 2018 Sep;67(9). – P. 1726–1738.
10. Holm, H. Uhlig. Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease / Holm H. Uhlig, Fiona Powrie // Annual Review of Immunology. – 2018. – Vol. 36. – P. 755–81.
11. Piovani, D. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses / D. Piovani, S. Danese, L. Peyrin-Biroulet [et al.] // Gastroenterology. – 2019. – Vol. 157. – P. 647–659.
12. Barnhoorn, M. C., Hakuno S. K., Bruckner R. S. et al. Stromal Cells in the Pathogenesis of Inflammatory Bowel Disease / M. C. Barnhoorn, S. K. Hakuno, R. S. Bruckner [et al.] // Journal of Crohn’s and Colitis. – 2020. – P. 1–15 doi:10.1093/ecco-jcc/jjaa009.
13. Gonçalves, F. Cell membrane and bioactive factors derived from mesenchymal stromal cells: Cell-free based therapy for inflammatory bowel diseases / F. Gonçalves, A. H. Paz // World J. Stem Cells. – 2019. – Sep 26; 11(9). – P. 618–633.
14. Munkholm, Pia. Findings from the European Collaborative Inflammatory Bowel Disease Database / Pia Munkholm // J. Gastroenterol Hepatol. – 2007. – Oct;3(10). – P. 760–762.
15. Pariente, В. Treatments for Crohn’s Disease–Associated Bowel Damage: A Systematic Review /В. Pariente, Hu Shurong, D. Bettenworth [et al.] // Clinical Gastroenterology and Hepatology. – 2019. – Vol. 17, Issue 5, April. – P. 847–856.
16. Le Blanc, K. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study / K. Le Blanc, F. Frassoni, L. Ball [et al.]. – Lancet. – 2008. – Vol. May 10;371(9624). – P. 1579–86.
17. Di Nicola, M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli / M. Di Nicola, C. Carlo-Stella, M. Magni [et al.] // Blood. – 2002. – Vol. 99. – Р. 3838–3843.
18. Abreu, S. C. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases / S. C. Abreu, D. J. Weiss, P. R. Rocco // Stem Cell Res Ther. – 2016. – Apr 14; № 7(1). – Р. 53.
19. Козлов, В. А. Триптофан и indoleamine-2,3-dioxygenase (IDO) в патогенезе иммунокомпрометированных заболеваний / В. А. Козлов, Д. В. Демина // Медицинская иммунология. – 2017. – Т. 19, № 3. – С. 225–240.
20. Ghannam, S. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype / S. Ghannam, J. Pene, G. Torcy-Moquet [et al.] // J. Immunol. – 2010. – Vol. 185(1). – P. 302–12.
21. Renner, P. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function / P. Renner, E. Eggenhofer, A. Rosenauer [et al.] //Transplant proc. – 2009. – Vol.41(6). – P. 2607–11.
22. Augello, A. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway / A. Augello, R. Tasso, S. M. Negrini [et al.] // Eur. J. Immunol. – 2005. – Vol. 35. – Р. 1482–1490.
23. Spaggiari, G. M. MSCs inhibit monocytederived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2 /G. M. Spaggiari, H. Abdelrazik, F. Becchetti [et al.] // Blood. – 2009. – Vol. 113. – Р. 6576–6583.
24. Zhang, Q. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis / Q. Zhang, S. Shi, Y. Liu [et al.] // J. Immunol. – 2009. – Vol. 183(12). – P. 7787–98.
25. Gonzalez-Rey, E. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis / E. Gonzalez-Rey, P. Anderson, M. A. Gonzalez [et al.] // Gut. – 2009. – Vol. 58(7). – P. 929–39.
26. Князев, О. В. Трансплантация мезенхимальных стромальных клеток костного мозга на модели язвенного колита / О. В. Князев, С. Г. Хомерики, И. Е. Трубицына, А. Г. Коноплянников // Экспериментальная и клиническая гастроэнтерология. – 2017. – № 144 (8). – C. 62–66.
27. Sala, E. Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine / E. Sala, M. Genua, L. Petti [et al.] // Gastroenterology. – 2015. – Vol. 149(1). – P. 163–176.
28. Choi, H. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages / H. Choi, R. H. Lee, N. Bazhanov [et al.] // Blood. – 2011. – Vol. Jul 14;118(2). – P. 330–8.
29. Garcia-Olmo, D. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy /D. Garcia-Olmo, M. Garcia-Arranz, L. G. Garcia [et al.] // Int J Colorectal Dis. – 2003. – Vol. 18. – P. 451–454.
30. Garcia-Olmo, D. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation / D. Garcia-Olmo, M. Garcia-Arranz, D. Herreros [et al.] // Dis Colon Rectum. – 2005. – Vol. 48. – P. 1416–1423.
31. Duijvestein, M. Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phaseI study / M. Duijvestein, A. C, Vos, H. Roelofs [et al.] // Gut. – 2010. – Vol. 59. – P. 1662–1669.
32. Dhere, T. The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease – a phase 1 trial with three doses / T. Dhere, I. Copland, M. Garcia [et al.] // Aliment Pharmacol Ther. – 2016. – Vol. 44. – P. 471–81.
33. Onken, J. Sucessful outpatient treatment of refractory Cron’s disease using adult mesenchymal stem cells / J. Onken, J. Hanson, M. Pandak, L. Custer // American College of Gastroenterology Annual Meeting. – 2006.
34. Князев, О. В. Использование мезенхимальных стромальных клеток в комплексной терапии язвенного колита/ О. В. Князев, В. И. Парфенов, А. Г. Коноплянников //Терапевтический архив. – 2016. – T. 88, № 2. – С. 44–48.
35. Forbes, G. M. A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn’s Disease Refractory to Biologic Therapy / G. M. Forbes, M. J. Sturm, R. W. Leong [et al.] // Clinical Gastroenterology and Hepatology. – 2014. – Vol. 12(1). – P. 64–71.
36. Liang, J. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease / J. Liang, H. Zhang, D. Wang [et al.] // Gut. – 2012. – Vol. 61. – P. 468–469. 36. Zhang, J. Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial / J. Zhang, S. Lv, X. Liu [et al.] // Gut Liver. – 2018. – Vol. 12(1). – P. 73–78.
37. Panes, J. Expanded allogeneic adipose derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial / J. Panes, D. Garcia-Olmo, G. Van Assche [et al.] // Lancet. – 2016. – Vol. 388. – P. 1281–90.
38. Panés, J., García-Olmo D., Van Assche G. et al. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease / J. Panés, D. García-Olmo, G. Van Assche [et al.] // Gastroenterology. – 2018. – Vol. 154(5). – P. 1334–1342.
39. Kotze, P. G. Darvadstrocel for the treatment of patients with perianal fistulas in Crohn’s disease / P. G. Kotze, A. Spinelli, J. Warusavitarne [еt al.] // Drugs Today (Barc). – 2019. – Vol. Feb;55(2). – P. 95–105.
40. Children’s National Medical Center Washington, District of Columbia, United States Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease // ClinicalTrials.gov., NCT 02150551.